Supplementary Figure 1

Assessment of the cytotoxic and hemotoxic effect of free and liposomal formulations of maduramicin. (A-B) Effect of varying concentrations of free and liposomal formulations of maduramicin on the growth of liver cancer cell line (HepG2) and human embryonic kidney cells (HEK-293) post 24 h exposure respectively. (C) Representative micrograph of hemolysis caused by varying concentrations of free and PEGylated liposomal formulation of maduramicin. (D) Percentage of hemolysis caused by various concentrations of free and liposomal formulations of maduramicin. Each dataset represents the average mean ± SD of three independent experiments.

Supplementary Figure 2

***In vitro* release profile of maduramicin from conventional and PEGylated liposomes in phosphate buffered saline (pH 7.4) at 37°C.**

Supplementary Figure 3

Uptake Studies of fluorescently labeled liposomal formulations by *P. falciparum* infected erythrocytes. (A) Quantitative estimation of internalization of NBD-PC tagged conventional and PEGylated liposomes by parasitized RBCs at different time intervals using spectrofluorometer. (B) Localization of fluorescently labeled liposome in parasite infected RBCs as detected by fluorescence microscopy at 100X magnification. DAPI stains the *Plasmodium* nuclei (blue) and NBD-PC (green).

Supplementary Figure 1 (S1)

Concentration of Maduramicin (µg/ml)	% Haemolysis FMAD	% Haemolysis CLMAD	% Haemolysis PLMAD
0.1	0	0	0
1	0	0	0
10	54±4	7±0.5	8.3±1
50	92±6.5	9±1	11±3.5

Supplementary Figure 2 (S2)

Supplementary Figure 3 (S3)

A

B

Bright Field (BF) DAPI NBD-PC DAPI + NBD-PC BF + DAPI + NBD-PC

Supplementary Table 1

Gene	Primer Sequence
GAPDH	*Forward 5'-GTGTGAACGGATTTGGCCGTATTG-3'* *Reverse 5'-TTTGCCGTGAGTGGAGTCATACTG-3'*
ICAM-I	*Forward 5'-CTCCGCTGCTACCTGCACTTT-3'* *Reverse 5'-AGTTCACCTGCACGGACCCAC-3'*
Granzyme B	*Forward 5'-CCTCCTGCTACTGCTGAC-3'* *Reverse 5'-GTCAGCACAAAGTCCTCTC-3'*
CXCR3	*Forward 5'-AATGCCACCCATTGCCAGTAC-3'* *Reverse 5'-AGCAGTAGGCCATGACCAGAAG-3'*
CXCL10	*Forward 5'-GACGGTCCGCTGCAACTG- 3'* *Reverse 5'-GCTTCCCTATGGCCCTCATT-3'*
TNF-α	*Forward 5'-AAGCCTGTAGCCCACGTCGTA-3'* *Reverse 5'-GGCACCACTAGTTGGTTGTCTTTG-3'*
IFN-γ	*Forward 5'-TCAAGTGGCATAGAGTGGAAGAA-3'* *Reverse 5'-TGGCTCTGCAGGATTTTCATG-3'*